Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2404175121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Shin-Ichiro Hattori und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, Drug Resistance, Viral. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Japan Agency for Medical Research and Development (AMED), National Center for Global Health and Medicine (NCGM).
Abstract (Originalsprache)
We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (M pro ) inhibitors (nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2 WK521 WT in VeroE6 TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles. A predominant E166V-carrying variant (SARS-CoV-2 WK521 E166V ), which emerged when passaged with nirmatrelvir and TKB245, proved to be resistant to the two inhibitors. A recombinant SARS-CoV-2 E166V was resistant to nirmatrelvir and TKB245, but sensitive to 5h. X-ray structural study showed that the dimerization of M pro was severely hindered by E166V substitution due to the disruption of the presumed dimerization-initiating Ser1’-Glu166 interactions. TKB245 stayed bound to M pro E166V , whereas nirmatrelvir failed. Native mass spectrometry confirmed that nirmatrelvir and TKB245 promoted the dimerization of M pro , and compromised the enzymatic activity; the Ki values of recombinant M pro E166V for nirmatrelvir and TKB245 were 117±3 and 17.1±1.9 µM, respectively, indicating that TKB245 has a greater (by a factor of 6.8) binding affinity to M pro E166V than nirmatrelvir. SARS-CoV-2 WK521 WT selected with 5h acquired A191T substitution in M pro (SARS-CoV-2 WK521 A191T ) and better replicated in the presence of 5h, than SARS-CoV-2 WK521 WT . However, no significant enzymatic or structural changes in M pro A191T were observed. The replicability of SARS-CoV-2 WK521 E166V proved to be compromised compared to SARS-CoV-2 WK521 WT but predominated over SARS-CoV-2 WK521 WT in the presence of nirmatrelvir. The replicability of SARS-CoV-2 WK521 A191T surpassed that of SARS-CoV-2 WK521 WT in the absence of 5h, confirming that A191T confers enhanced viral fitness. The present data should shed light on the understanding of the mechanism of SARS-CoV-2’s drug resistance acquisition and the development of resistance-repellant COVID-19 therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
- Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD 20892.
- Division of Infectious Diseases, International Research Institute of Disaster Science, Tohoku University, Miyagi 980-8575, Japan.
- Department of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
- Structural Biology Division, Japan Synchrotron Radiation Research Institute, Hyogo 679-5198, Japan.
- Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
ORCID-Profile: Shin-Ichiro Hattori, Haydar Bulut, Hironori Hayashi, Nobutoki Takamune, Kazuya Hasegawa, Kazutaka Murayama, Hirokazu Tamamura, Alexander Wlodawer, Yoshihiro Kawaoka
Förderung
- NCI NIH HHS
- Japan Agency for Medical Research and Development (AMED)
- National Center for Global Health and Medicine (NCGM)
- CCR NIH HHS
- HHS | NIH | National Cancer Institute
Zitieren
APA
Hattori, S. I., Bulut, H., Hayashi, H., Kishimoto, N., Takamune, N., Hasegawa, K., Furusawa, Y., Yamayoshi, S., Murayama, K., Tamamura, H., Li, M., Wlodawer, A., Kawaoka, Y., Misumi, S., & Mitsuya, H. (2024). Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2404175121
Vancouver
Hattori SI, Bulut H, Hayashi H, Kishimoto N, Takamune N, Hasegawa K, et al. Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2404175121
BibTeX
@article{Hattori2024,
author = {Hattori, Shin-Ichiro and Bulut, Haydar and Hayashi, Hironori and Kishimoto, Naoki and Takamune, Nobutoki and Hasegawa, Kazuya and Furusawa, Yuri and Yamayoshi, Seiya and Murayama, Kazutaka and Tamamura, Hirokazu and Li, Mi and Wlodawer, Alexander and Kawaoka, Yoshihiro and Misumi, Shogo and Mitsuya, Hiroaki},
title = {Structural and virologic mechanism of the emergence of resistance to M pro inhibitors in SARS-CoV-2},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2404175121}
}
EUVIMED